Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP plus Bevacizumab in Advanced Stage DLBCL
NCT00121199Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Jun 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00121199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121199.